| REVIEW ARTICLE |
|
| Year : 2021 | Volume
: 8
| Issue : 1 | Page : 8-13 |
|
|
Use of immunosuppressants in vitiligo during COVID-19 pandemic: a quick review
Hitaishi Mehta1, KT Soufila1, Sheetanshu Kumar1, Rashmi Sarkar2, Muthu Sendhil Kumaran1
1 Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
2 Department of Dermatology, LHMC and Associated KSCH and SSK Hospital, New Delhi, India
Correspondence Address:
Muthu Sendhil Kumaran
Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh 160012
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/pigmentinternational.pigmentinternational_
|
|
|
Owing to the recent coronavirus (COVID-19) pandemic, there is a concern regarding the use of systemic immunosuppressive agents. There are no guidelines at present regarding the use of immunosuppressants. The main aim at this time should be to keep the dermatoses under control without exposing the patient to increased risk of infection and the consequent morbidity. In vitiligo, immunosuppressive agents are utilized in stabilization of progressive disease. An informed decision regarding the use of immunosuppressive agents can be made only after understanding the immune response to coronavirus, reviewing the mechanism of action of drug and evidence from previous studies on risk of infection. This review briefly discusses the mechanism of action and the safety data of various immunosuppressants used in vitiligo.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
